VitroScan secures funding from Biotech Booster program to deliver chemotherapy response prediction for ovarian cancer patients

VitroScan, a Leiden-based biotech company, announced that it has received funding from Biotech Booster to deliver chemotherapy response prediction for ovarian cancer patients. The funding will assist in preparing for clinical use and ensuring the service meets quality and regulatory standards for patients.